Articles by Jan E. Berger, MD, MJ

To mark the 30th anniversary of The American Journal of Managed Care (AJMC), each issue in 2025 includes a special feature: reflections from a thought leader on what has changed—and what has not—over the past 3 decades and what’s next for managed care. The January issue features a conversation with longtime editorial board member Jan E. Berger, MD, MJ, the CEO of Health Intelligence Partners.

As health care moves toward a value-based payment model, the pharmacy benefit is going in the opposite direction, one that places unit cost over clinical appropriateness.


This article addresses what employers need to know about food as medicine and offers practical steps to reduce barriers for their employee populations.


Comparative Effectiveness Research and Formulary Placement: The Case of Diabetes
ByMichael E. Chernew, PhD,Rick McKellar, BS,Wade Aubry, MD,Roy Beck, MD, PhD,Joshua Benner, PharmD, ScD,Jan E. Berger, MD, MJ,A. Mark Fendrick, MD,Felicia Forma, BSc,Dana Goldman, PhD,Anne Peters, MD,Rebecca Killion, MA,Darius Lakdawalla, PhD,Douglas K. Owens, MD,Joe Stahl, MA 
Comparative Effectiveness Research and Formulary Placement: The Case of Diabetes
ByMichael E. Chernew, PhD,Rick McKellar, BS,Wade Aubry, MD,Roy Beck, MD, PhD,Joshua Benner, PharmD, ScD,Jan E. Berger, MD, MJ,A. Mark Fendrick, MD,Felicia Forma, BSc,Dana Goldman, PhD,Anne Peters, MD,Rebecca Killion, MA,Darius Lakdawalla, PhD,Douglas K. Owens, MD,Joe Stahl, MA Formularies of the future should use evidence-produced CER to better target, not limit, diabetes care.

Prescriber Compliance With Black Box Warnings in Older Adult Patients
ByJudith A. Ricci, ScD, MS,Charmaine Coulen, MPH,Jan E. Berger, MD, MJ,Marsha C. Moore, MD, MBA,Angela McQueen, PharmD,Saira A. Jan, PharmD
Elderly patients prescribed drugs with a drug-laboratory black box warning (BBW) had lower rates of prescriber BBW compliance than patients prescribed drugs with a drug-disease warning.